Arena Pharmaceuticals Inc. (ARNA)

50.75
0.32 0.63
NASDAQ : Health Technology
Prev Close 51.07
Open 51.16
Day Low/High 50.26 / 51.84
52 Wk Low/High 31.97 / 64.48
Volume 106.11K
Avg Volume 456.50K
Exchange NASDAQ
Shares Outstanding 49.83M
Market Cap 2.55B
EPS -0.60
P/E Ratio 4.45
Div & Yield N.A. (N.A)
Market News: Arena Pharmaceuticals, Dupont, Illumina

Market News: Arena Pharmaceuticals, Dupont, Illumina

The stock markets in the United States declined today except the Dow Jones Industrial Average (DJIA), up by 0.08 as energy shares rally due to the increase in crude oil prices. Sign up for our free ne...

10 Worst NASDAQ Biotech Stocks in the Third Quarter

10 Worst NASDAQ Biotech Stocks in the Third Quarter

The third quarter was brutal for biotech stocks. Here are the companies that fared the worst.

Arena Pharmaceuticals (ARNA) Highlighted As Weak On High Volume

Arena Pharmaceuticals (ARNA) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate

Cannabis Companies Hunt for Financing, Growth

Cannabis Companies Hunt for Financing, Growth

Companies in the cannabis business have an appetite for capital to fuel what has emerged as one of the largest growth sectors, and more investors are taking the risk.

Arena Pharmaceuticals Stock Sees Short Interest Decrease By 10.8%

Arena Pharmaceuticals Stock Sees Short Interest Decrease By 10.8%

The most recent short interest data has been released by the NASDAQ for the 08/31/2015 settlement date, which shows a 3,064,041 share decrease in total short interest for Arena Pharmaceuticals Inc , to 25,269,668, a decrease of 10.81% since 08/14/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

'Fast Money' Recap: Countdown to a Fed Rate Increase

'Fast Money' Recap: Countdown to a Fed Rate Increase

The trading panel discussed why the Federal Reserve should announce a rate hike at its September meeting and wondered if Twitter will ever get a new CEO in place.

Biogen Takes on Celgene With New Autoimmune License Deal

Biogen Takes on Celgene With New Autoimmune License Deal

Biogen stepped into the oral S1P modulator race Wednesday with the acquisition of a license to develop a mid-stage compound from Japan's Mitsubishi Tanabe Pharma.

Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock

Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate

Biotech Stock Mailbag: Controversial Stocks Revisited

Biotech Stock Mailbag: Controversial Stocks Revisited

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Arena Pharmaceuticals (ARNA) Showing Signs of Perilous Reversal Today

Arena Pharmaceuticals (ARNA) Showing Signs of Perilous Reversal Today

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a "perilous reversal" (up big yesterday but down big today) candidate

3 Biotech Stocks to Trade Off the Receptos Buyout

3 Biotech Stocks to Trade Off the Receptos Buyout

Three biotech stocks are trading on big volume following news that Celgene will acquire Receptos. Here's how to trade them now.

Analysts Break Down Impact Of $7.2B Receptos Buyout

Analysts Break Down Impact Of $7.2B Receptos Buyout

After Celgene announced last night that the company has agreed to acquire Receptos for $232 per share in cash, research firms have chimed in with their opinions...

Commit To Purchase Arena Pharmaceuticals At $2.50, Earn 10.8% Using Options

Commit To Purchase Arena Pharmaceuticals At $2.50, Earn 10.8% Using Options

Investors considering a purchase of Arena Pharmaceuticals Inc shares, but tentative about paying the going market price of $4.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $2.50 strike, which has a bid at the time of this writing of 27 cents.

Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock

Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate

Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume

Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate

Arena Pharmaceuticals (ARNA) Stock Declines on CFO Departure

Arena Pharmaceuticals (ARNA) Stock Declines on CFO Departure

Arena Pharmaceuticals (ARNA) shares are falling after the company announced that CFO Robert Hoffman will be leaving the company after 18 years.

Commit To Purchase Arena Pharmaceuticals At $3, Earn 18.3% Using Options

Commit To Purchase Arena Pharmaceuticals At $3, Earn 18.3% Using Options

Investors eyeing a purchase of Arena Pharmaceuticals Inc shares, but cautious about paying the going market price of $4.48/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $3 strike, which has a bid at the time of this writing of 55 cents.

Arena Pharmaceuticals (ARNA) Stock Gains Today on New Patent Approval

Arena Pharmaceuticals (ARNA) Stock Gains Today on New Patent Approval

Arena Pharmaceuticals (ARNA) shares are rising after the U.S. Patent and Trademark Office granted approval for a new patent for its weight loss treatment, Belviq.

Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate

Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock

Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.

Arena Pharmaceuticals (ARNA) Stock: Weak On High Volume Today

Arena Pharmaceuticals (ARNA) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.

Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics

Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics

Biotech columnist Adam Feuerstein answers readers' questions about health care.

4 Big Stocks to Trade for Gains (or Not): Petrobras, AMD and More

4 Big Stocks to Trade for Gains (or Not): Petrobras, AMD and More

Here's how to trade some of the most active stocks today.

ARNA Makes Notable Cross Below Critical Moving Average

ARNA Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of Arena Pharmaceuticals Inc crossed below their 200 day moving average of $4.93, changing hands as low as $4.75 per share. Arena Pharmaceuticals Inc shares are currently trading off about 9.3% on the day.

Arena Pharmaceuticals (ARNA) Weak On High Volume Today

Arena Pharmaceuticals (ARNA) Weak On High Volume Today

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate

Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock

Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a pre-market leader candidate

Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock

Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

TheStreet Quant Rating: C+ (Hold)